N2103

Main purpose of the trial: To preliminarily study the pharmacokinetic characteristics of the test drug N2103 enteric-coated capsules (specification: 10 mg) and the control drug (specification: 5 mg) when taken orally in the fasting state in healthy participants, so as to provide a reference for the later development strategy. Secondary purpose of the trial: To preliminarily study the safety of the test drug N2103 enteric-coated capsules (specification: 10 mg) and the control drug (specification: 5 mg) in healthy participants.